Pembrolizumab

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoma, Unspecified Site

Conditions

Carcinoma, Unspecified Site

Trial Timeline

Feb 1, 2018 → Mar 2, 2023

NCT ID

NCT03396471

About Pembrolizumab

Pembrolizumab is a phase 2 stage product being developed by Merck for Carcinoma, Unspecified Site. The current trial status is terminated. This product is registered under clinical trial identifier NCT03396471. Target conditions include Carcinoma, Unspecified Site.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02083484	Pre-clinical	Completed	—	—	Melanoma
NCT07302347	Phase 1/2	Recruiting	Mar 31, 2026	Dec 31, 2029	Malignant Neoplasm
NCT07089992	Phase 2	Recruiting	Dec 4, 2025	Dec 1, 2028	Sarcoma
NCT07007273	Phase 2	Recruiting	Jun 20, 2025	Jul 1, 2030	Cutaneous Sarcoma
NCT04569461	Phase 2	Withdrawn	Jun 1, 2025	Dec 1, 2026	Prostate Cancer
NCT05815927	Phase 3	Recruiting	May 23, 2025	Mar 30, 2030	Oligometastatic Squamous Cell Carcinoma of the Head and Neck
NCT05852223	Phase 2	Recruiting	Dec 20, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT05879120	Phase 2	Withdrawn	Jul 30, 2024	Oct 2, 2024	Recurrent Glioblastoma
NCT06004336	Phase 2	Recruiting	Oct 31, 2023	Jan 1, 2029	Oligometastatic Renal Cell Carcinoma
NCT05496036	Phase 2	Recruiting	Feb 13, 2023	Sep 30, 2027	Merkel Cell Carcinoma
NCT05131919	Phase 2	Active	Dec 22, 2022	Jul 1, 2031	Colorectal Cancer
NCT05197322	Phase 2	Recruiting	Jul 20, 2022	Dec 1, 2028	Adenocarcinoma of the Colon
NCT05406713	Phase 2	Active	Jul 13, 2022	Jan 1, 2028	Muscle Invasive Bladder Carcinoma
NCT05025813	Phase 2	Recruiting	Jun 28, 2022	Jun 1, 2027	Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT06413095	Phase 1	Completed	Jun 1, 2022	Jun 22, 2023	Head and Neck Squamous Cell Carcinoma
NCT05191472	Phase 2	Terminated	May 3, 2022	Dec 31, 2023	Multiple Myeloma
NCT05204160	Phase 2	Withdrawn	Apr 11, 2022	Feb 27, 2024	Plasma Cell Myeloma
NCT04575961	Phase 2	Active	Feb 22, 2022	Mar 1, 2028	Ovarian Cancer
NCT04417166	Phase 2	Recruiting	Feb 11, 2022	Dec 1, 2026	Lymphoma, Extranodal NK-T-Cell
NCT05188508	Phase 2	Recruiting	Jan 14, 2022	Jan 1, 2027	Glioma

Competing Products

20 competing products in Carcinoma, Unspecified Site

See all competitors

Product	Company	Stage	Hype Score
AFM24 + SNK01	Affimed	Phase 1/2	33
NRC-2694-A + Paclitaxel	Natco Pharma	Phase 2	51
Sintilimab + Nab paclitaxel + Cisplatin	CSPC Pharmaceutical Group Limited	Phase 2	51
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	30
Pemetrexed + Carboplatin	Eli Lilly	Phase 3	77
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells	Precigen	Phase 1	28
Cemiplimab + Cetuximab	Eli Lilly	Phase 2	52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU	Eli Lilly	Phase 2	52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
CT-01 + EVEROLIMUS	Captor Therapeutics	Phase 1	25
BB-401	Benitec Biopharma	Phase 2	44
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	44
Azenosertib	Zentalis Pharmaceuticals	Phase 2	44
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	69
ateganosine + Cadonilimab	MAIA Biotechnology	Phase 1	25
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	52
Cetuximab	Eli Lilly	Phase 1	33
Ramucirumab + Paclitaxel	Eli Lilly	Phase 2	52
LY2875358 + Erlotinib	Eli Lilly	Phase 2	52

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved